The agreement pledges new areas of cooperation such as an exchange of learning from the accelerated access review (AAR) and how to effectively regulate the trading of medicines online. The renewed signing expands on a MoU which originated from 2014.

Dr Ian Hudson, Chief Executive Officer at MHRA who signed the Agreement for the UK said:
“China is a world leader in the market for raw materials for the pharmaceutical industry and closer collaboration with MHRA will support the promotion of innovation, good practice, and protect UK patients.” He added that “We operate in a global environment and formalising our international relationships helps strengthen regulatory systems to protect public health worldwide.”

In times of Brexit, the MHRA has to make its own moves towards establishing international partnerships. This seems to be well on the way, even though the negotiations with the EU are still in progress.

Source:

MHRA: Press Release

CFDA: What's new